Early Adjuvant Immunotherapy Discontinuation Does Not Affect Melanoma Recurrence Risk
Source: AJMC, April 2025
Recurrence-free survival rates were similar, even when patients quit adjuvant immunotherapy early, according to a new report.
Patients who receive adjuvant immunotherapy following metastatic melanoma resection do not experience inferior outcomes if they stop immunotherapy after less than 12 months, a new study has found. The study, which was published in the Journal of the European Academy of Dermatology and Venereology, suggests that patients who develop adverse events while taking adjuvant therapy may not benefit from continuing treatment.
The study authors explained that patients with melanoma face a significant risk of recurrence following resection, particularly if they have distant metastatic melanoma.2 Recurrence brings a high risk of mortality, depending on the cancer’s stage.